Olmesartan Medoxomil/Amlodipine/Hydrochlorothiazide Accord (Olmesartan Medoxomil, Amlodipine, Hydrochlorothiazide)

Olmesartan medoxil, the active ingredient in Olmesartan Medoxomil/Amlodipine/Hydrochlorothiazide Accord, is a angiotensin II receptor blocker presented as a combination tablet for oral use. It treats hypertension, often in patients who require multiple mechanisms of blood pressure control. GNH USA supplies Olmesartan Medoxomil/Amlodipine/Hydrochlorothiazide Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

GNH USA supplies Olmesartan Medoxomil/Amlodipine/Hydrochlorothiazide Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Olmesartan Medoxil/Amlodipine/Hydrochlorothiazide is used in the management of hypertension, targeting several physiological pathways that regulate blood pressure. - Hypertension: improves blood pressure control when monotherapy is insufficient. - Hypertensive heart disease: reduces cardiac workload and risk of progression. - Chronic kidney disease with hypertension: helps slow renal function decline associated with high blood pressure.

Adverse reactions may vary depending on the individual component and patient characteristics.

Common Side Effects: - Dizziness or light‑headed headache. - Peripheral edema, especially related to amlodipine. - Cough or mild upper‑respiratory irritation. - Increased urination or electrolyte changes. - Fatigue or general weakness. - Mild gastrointestinal discomfort.

Serious or Rare Side Effects: - Severe hypotension or syncope. - Acute kidney injury or significant rise in serum creatinine. - Hyperkalemia or severe electrolyte imbalance. - Angio‑edema involving the face, lips or airway. - Hepatotoxicity presenting as jaundice or abnormal liver enzymes. - Blood dyscrasias such as agranulocytosis or thrombocytopenia.

When prescribing this combination, clinicians should consider patient history, comorbidities, and concurrent therapies. - Renal impairment: adjust monitoring and avoid excessive diuretic use. - Hepatic dysfunction: use with caution; monitor liver enzymes. - Electrolyte disturbances: check serum potassium and sodium regularly. - Pregnancy: contraindicated in the second and third trimesters; avoid use. - Elderly patients: start at lower doses and monitor for orthostatic hypotension. - Store below 25°C: keep in the original packaging, protect from moisture and light.

Olmesartan Medoxil/Amlodipine/Hydrochlorothiazide may interact with several drug classes.

Major Interactions (Avoid): - Dual renin‑angiotensin system blockade (e.g., ACE inhibitors, other ARBs): risk of renal failure and hyperkalaemia. - Potassium‑sparing diuretics or supplements: may cause dangerous hyperkalaemia. - Strong CYP3A4 inhibitors (e.g., itraconazole, clarithromycin): increase amlodipine levels.

Moderate Interactions (Monitor Closely): - Non‑steroidal anti‑inflammatory drugs (NSAIDs): may reduce antihypertensive effect and impair renal function. - Lithium: increased risk of lithium toxicity. - Antidiabetic agents: may enhance hypoglycaemic effect. - Antacids containing aluminium or magnesium: may affect absorption of olmesartan. - Alcohol: additive vasodilatory effect leading to dizziness.